Company intelligence

PLX

Protalix BioTherapeutics, Inc. · AMEX · Healthcare

Price$2.59+0.78% · +$0.02

Market cap208.68MEquity value

P / E11.3Trailing ratio

Volume598.25KLatest session

Market data

PLX price chart

TradingView

Related signals

1 min delayed

Browse public PLX signals with their source context and measured market impact. Open any signal for its permanent analysis page.

PLXOct 17, 2025+8.82% since signal

Why Is Protalix BioTherapeutics Stock Falling On Friday?

EMA issued a negative opinion on PLX's Elfabrio dosing schedule. PLX stock price has dropped 29.83% to $1.68. Dosing regimen of Elfabrio 2 mg/kg every 4 weeks was not approved. Negative opinion impacts PLX amidst ongoing Fabry disease competition. Historical data from studies deemed insufficient by EMA for dosing approval.

View signal analysis

PLXMar 17, 2025-5.62% since signal

Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond

PLX reported 4 cents earnings, beating consensus of 1 cent. Fiscal 2024 sales reached $53.40 million, up 31% year-over-year. Revenue growth driven by sales increases to Chiesi, Brazil, and Pfizer. Protalix has promising results for PRX-115 gout candidate, aiming for phase II trial. Company's debt repaid, strengthening balance sheet for future strategies.

View signal analysis

Research